ABSTRACT
Public spending accounts for 50 to 80% of pharmaceutical expenditures in Western Europe; the balance is made up by private health insurance and out-of-pocket payments by patients (OECD 2008). In practice, this means that obtaining reimbursement from public healthcare systems is imperative for commercial success in the European Union (EU).
